Risankizumab significantly improves patient-reported outcomes in moderate to severe psoriasis in two phase III UltIMMa trials

被引：0
|
作者：
Augustin, M. [1 ]
Lambert, J. [2 ]
Zema, C. [3 ]
Thompson, E. H. [3 ]
Yang, M. [4 ]
Wu, E. [4 ]
Geng, Z. [3 ]
Valdes, J. [3 ]
Skup, M. [3 ]
Gordon, K. [5 ]
机构：
[1] Univ Klinikum Hambrg Eppendorf, IVDP, Hambug, Germany
[2] Ghent Univ Hosp, Ghent, Belgium
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Boston, MA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P102
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [1] Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
    Augustin, Matthias
    Lambert, Jo
    Zema, Carla
    Thompson, Elizabeth H. Z.
    Yang, Min
    Wu, Eric Q.
    Garcia-Horton, Viviana
    Geng, Ziqian
    Valdes, Joaquin M.
    Joshi, Avani
    Gordon, Kenneth B.
    [J]. JAMA DERMATOLOGY, 2020, 156 (12) : 1344 - 1353
  • [2] Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
    Thaci, D.
    Kimball, A.
    Foley, P.
    Poulin, Y.
    Levi, E.
    Chen, R.
    Feldman, S. R.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 498 - 506
  • [3] Treatment with etanercept improves patient-reported outcomes in patients with moderate to severe psoriasis
    Gottlieb, A
    Woolley, JM
    Lalla, D
    Jahreis, A
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P201 - P201
  • [4] Characterization of Patient-reported Outcomes in moderate to severe Psoriasis
    Radtke, M. A.
    Schmitt-Rau, K. H.
    Krenzer, S.
    Augustin, M.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 126 - 126
  • [5] Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis
    Krenzer, Stefanie
    Radtke, Marc
    Schmitt-Rau, Karlheinz
    Augustin, Matthias
    [J]. DERMATOLOGY, 2011, 223 (01) : 80 - 86
  • [6] Real-world patient-reported outcomes with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
    Strober, Bruce
    Ferris, Laura K.
    Duffin, Kristina Callis
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB101 - AB101
  • [7] Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: Pooled results from three randomized phase III trials
    Menter, A
    Hamilton, T
    Caro, I
    Chen-Rundle, A
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [8] Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
    Reich, K.
    DeLozier, A. M.
    Nunes, F. P.
    Thyssen, J. P.
    Eichenfield, L. F.
    Wollenberg, A.
    Terres, J. A. Ross
    Watts, S. D.
    Chen, Y-F
    Simpson, E. L.
    Silverberg, J., I
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1521 - 1530
  • [9] Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
    Revicki, Dennis A.
    Willian, Mary Kaye
    Menter, Alan
    Gordon, Kenneth B.
    Kimball, Alexa B.
    Leonardi, Craig L.
    Langley, Richard G.
    Kimel, Miriam
    Okun, Martin
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2007, 18 (06) : 341 - 350
  • [10] Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naive patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
    Thaci, D.
    Soliman, A. M.
    Eyerich, K.
    Pinter, A.
    Sebastian, M.
    Unnebrink, K.
    Rubant, S.
    Williams, D. A.
    Weisenseel, P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (08) : 1686 - 1691
12345